Prognostic factors in patients after definitive chemoradiation using involved‐field radiotherapy for esophageal cancer in a phase II study
Autor: | Hideomi Yamashita, Ryousuke Takenaka, Kae Okuma, Kuni Ootomo, Keiichi Nakagawa |
---|---|
Rok vydání: | 2016 |
Předmět: |
Male
Esophageal Neoplasms Organoplatinum Compounds medicine.medical_treatment Gastroenterology chemistry.chemical_compound 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols esophageal cancer Prospective Studies Prospective cohort study Aged 80 and over Univariate analysis General Medicine Middle Aged Esophageal cancer Prognosis Primary tumor Treatment Outcome Oncology Lymphatic Metastasis 030220 oncology & carcinogenesis Original Article Female 030211 gastroenterology & hepatology Fluorouracil Adult Pulmonary and Respiratory Medicine medicine.medical_specialty gross tumor volume relative dose intensity Definitive chemoradiotherapy Disease-Free Survival Young Adult 03 medical and health sciences Internal medicine medicine Humans Nedaplatin Aged involved‐field radiotherapy business.industry Dose fractionation Original Articles medicine.disease Radiation therapy chemistry Dose Fractionation Radiation Neoplasm Grading business Nuclear medicine Chemoradiotherapy |
Zdroj: | Thoracic Cancer |
ISSN: | 1759-7714 1759-7706 |
Popis: | Background A prospective study was performed on the use of chemoradiotherapy (CRT) for esophageal cancer (EC) with involved‐field radiation therapy (IFRT), based on 18‐fluorodeoxyglucose positron‐emission tomography. Prognostic factors for overall survival (OS) were analyzed. Methods Eligible patients included 63 adults with newly diagnosed, untreated, inoperable stage I–IV EC with lymph node metastases. Patients received 80 mg/m2 nedaplatin per day on day 1, 800 mg/m2 5‐fluorouracil on days 1–4 intravenously repeated every 28 days for two to four cycles, and combined IFRT. Irradiation was applied only to the primary tumor and positive lymph nodes. Results Three‐year progression‐free survival and OS rates were 44.9% and 47.5%, respectively. The median survival time was 31.5 months. In univariate analyses for OS, Karnofsy Performance Scale 1.5 ng/mL (P = 0.0054), gross tumor volume (GTV) > 60 cc (P = 0.00011), and relative dose intensity (RDI) of chemotherapy ≤50% (P = 0.063) were found to be associated with significantly or marginally worse OS. In multivariate analyses for OS, GTV ≥ 60 cc (P = 0.00040), RDI < 50% (P = 0.00034), and cN2‐3 (P = 0.0020) were associated with significantly worse OS. Conclusion GTV, RDI and N grading, were associated with OS after definitive CRT using IFRT for EC. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |